Inimmune Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
36
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$2M
- Investors
-
4
Inimmune General Information
Description
Operator of a biotechnology company intended to offer treatment for allergy, autoimmunity, and cancer in patients. The company focuses on the prevention of upper respiratory tract infections by targeting innate immune receptors, enabling medical researchers to easily find a cure for patients with respiratory illnesses.
Contact Information
Website
www.inimmune.comCorporate Office
- 1121 East Broadway Street
- Suite 106
- Missoula, MT 59802
- United States
Corporate Office
- 1121 East Broadway Street
- Suite 106
- Missoula, MT 59802
- United States
Inimmune Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Grant | 02-Feb-2022 | $2M | Completed | Clinical Trials - Phase 1 | ||
| 6. Later Stage VC (Series A) | 02-Feb-2022 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 01-Jan-2021 | Completed | Clinical Trials - Phase 1 | |||
| 4. Grant | 01-Jan-2019 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | 09-Feb-2018 | Completed | Clinical Trials - Phase 1 | |||
| 2. Grant | 01-Jan-2018 | $769K | Completed | Clinical Trials - Phase 1 | ||
| 1. Accelerator/Incubator | 01-Jan-2016 | Completed | Clinical Trials - Phase 1 |
Inimmune Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A2 | ||||||||
| Series A1 |
Inimmune Patents
Inimmune Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026193322-A1 | Semi-synthetic saponin compounds | Pending | 12-Mar-2025 | ||
| WO-2025240407-A1 | Intranasal administration of toll-like receptor 4 agonists for treating allergic rhinitis and other diseases and conditions | Pending | 14-May-2024 | ||
| AU-2025207658-A1 | Functionalized imidazopyrimidine compounds and uses thereof | Pending | 10-Jan-2024 | ||
| WO-2025151620-A1 | Functionalized imidazopyrimidine compounds and uses thereof | Inactive | 10-Jan-2024 | ||
| EP-4561992-A2 | Stimulator of interferon genes agonists | Pending | 25-Jul-2022 | A61K31/5415 |
Inimmune Signals
Inimmune Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| McWin Partners | Family Office | Minority | ||
| Two Bear Capital | Venture Capital | Minority | ||
| National Institute Of Allergy and Infectious Diseases | Government | |||
| U.S. Department of Health and Human Services | Government |
Inimmune FAQs
-
When was Inimmune founded?
Inimmune was founded in 2016.
-
Where is Inimmune headquartered?
Inimmune is headquartered in Missoula, MT.
-
What is the size of Inimmune?
Inimmune has 36 total employees.
-
What industry is Inimmune in?
Inimmune’s primary industry is Drug Discovery.
-
Is Inimmune a private or public company?
Inimmune is a Private company.
-
What is Inimmune’s current revenue?
The current revenue for Inimmune is .
-
How much funding has Inimmune raised over time?
Inimmune has raised $22M.
-
Who are Inimmune’s investors?
McWin Partners, Two Bear Capital, National Institute Of Allergy and Infectious Diseases, and U.S. Department of Health and Human Services have invested in Inimmune.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process